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Abstract: Diabetes mellitus is associated with an increased risk of cardiovascular disease, 
even in the presence of intensive glycemic control. Substantial clinical and experimental 
evidence suggest that both diabetes and insulin resistance cause a combination of endothelial 
dysfunctions, which may diminish the anti-atherogenic role of the vascular endothelium. Both 
insulin resistance and endothelial dysfunction appear to precede the development of overt 
hyperglycemia in patients with type 2 diabetes. Therefore, in patients with diabetes or insulin 
resistance, endothelial dysfunction may be a critical early target for preventing atherosclerosis 
and cardiovascular disease. Microalbuminuria is now considered to be an atherosclerotic risk 
factor and predicts future cardiovascular disease risk in diabetic patients, in elderly patients, 
as well as in the general population. It has been implicated as an independent risk factor for 
cardiovascular disease and premature cardiovascular mortality for patients with type 1 and type 2 
diabetes mellitus, as well as for patients with essential hypertension. A complete biochemical 
understanding of the mechanisms by which hyperglycemia causes vascular functional and struc-
tural changes associated with the diabetic milieu still eludes us. In recent years, the numerous 
biochemical and metabolic pathways postulated to have a causal role in the pathogenesis of 
diabetic vascular disease have been distilled into several unifying hypotheses. The role of chronic 
hyperglycemia in the development of diabetic microvascular complications and in neuropathy 
has been clearly established. However, the biochemical or cellular links between elevated 
blood glucose levels, and the vascular lesions remain incompletely understood. A number of 
trials have demonstrated that statins therapy as well as angiotensin converting enzyme inhibi-
tors is associated with improvements in endothelial function in diabetes. Although antioxidants 
provide short-term improvement of endothelial function in humans, all studies of the effec-
tiveness of preventive antioxidant therapy have been disappointing. Control of hyperglycemia 
thus remains the best way to improve endothelial function and to prevent atherosclerosis and 
other cardiovascular complications of diabetes. In the present review we provide the up to date 
details on this subject.
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Introduction
Isolated diabetes mellitus is a frequent and increasing public health problem. 
Importantly, diabetes has a prevalence of 2%–5% in most Western countries, and is 
rapidly increasing in Asiatic countries due to changes in dietary habits during the last 
years (Contreras et al 2000).
Over the last two decades it has become evident that the endothelium is not an 
inert, single-cell lining covering the internal surface of blood vessels, but in fact plays 
a crucial role in regulating vascular tone and structure. Importantly, a healthy endo-
thelium inhibits platelet and leukocyte adhesion to the vascular surface and maintains 
a balance of proﬁ  brinolytic and prothrombotic activity (Libby 2002).
Endothelial dysfunction has received increasing attention as a potential con-
tributor to the pathogenesis of vascular disease in diabetes mellitus. Under physi-
ological conditions, there is a balanced release of endothelial-derived relaxing and Vascular Health and Risk Management 2007:3(6) 854
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contracting factors, but this delicate balance is altered in 
diabetes and atherosclerosis, thereby contributing to further 
progression of vascular and end-organ damage (Tan, Chow, 
Ai et al 2002).
Hyperglycemia is the major causal factor in the devel-
opment of endothelial dysfunction in diabetes mellitus. 
Although the mechanisms underlying this phenomenon 
are likely to be multifactorial. Insulin resistance has been 
described in several diseases that increase cardiovascular 
risk and mortality, such as diabetes, obesity, hypertension, 
metabolic syndrome, and heart failure.
Increasing evidence suggests that the progression of 
insulin resistance to type 2 diabetes parallels the progres-
sion of endothelial dysfunction to atherosclerosis. Insulin 
resistance is closely linked with visceral adiposity, and early 
data suggested that free fatty acids were responsible for this 
association (Boden and Shulman 2002). More recently, other 
plasma biomarkers produced by adipose tissue, including 
TNF and resistin, have been shown to have elevated levels 
during obesity and to mediate insulin resistance. Conversely, 
the expression and secretion of adiponectin, an adipocyte-
speciﬁ  c protein that enhances insulin-mediated glucose 
uptake, is inversely correlated with fat mass (Lyon et al 
2003). Several studies have demonstrated that nitric oxide 
(NO)-mediated vasodilation is abnormal in patients with type 
2 diabetes (Williams et al 1996). Brachial artery responses 
were found to be abnormal to both endogenous and exog-
enous NO donors, suggesting that there was increased inac-
tivation of NO, possibly caused by enhanced metabolism 
of NO or abnormal vascular smooth muscle cell (VSMC) 
responses to NO because of alterations in signal transduction 
in the guanylate cyclase pathway. Obese patients without 
frank type 2 diabetes have been shown also to have abnormal 
endothelial function (Steinberg et al 1996; Perticone et al 
2001). Herein, we review the literature about endothelial 
dysfunction in diabetes mellitus with regards to its pathogen-
esis at molecular and clinical level, and possible available 
mode of therapy.
Normal endothelial cell (EC) 
function
The EC is no longer considered a simple barrier. In fact it 
is a complex organ, with paracrin and autocrin function, 
which provides a “ﬁ  rst line” physiological defense against 
atherosclerosis. The EC lines the internal lumen of all the 
vasculature and serves as an interface between circulating 
blood and vascular smooth muscle cells (VSMC). In addition 
to serving as a physical barrier between the blood and tissues, 
the EC facilitates a complex array of functions in intimate 
interaction with the VSMC, as well as cells within the blood 
compartment (Vanhoutte 1995; De Meyer and Herman 1997; 
Haller 1997; Mombouli 1997).
The last two decades of research have established unam-
biguously that the EC has a critical role in overall homeostasis 
whose functions are integrated by a complicated system of 
chemical mediators. This system exerts effects on both the 
surrounding VSMC and the cells in the blood that lead to 
one or more of the following alterations: (1) vasodilatation 
or vasoconstriction to regulate organ blood, (2) maintenance 
of ﬂ  uidity of blood and avoidance of bleeding, (3) proin-
ﬂ  ammatory or anti-inﬂ  ammatory changes, and (4) growth 
and/or changes in the phenotypic characteristics of VSMC 
(Wautier et al 1983, 1990, 1996; Conger 1994; Chappey 
1996; De Meyer and Herman 1997).
During the last decade, a multitude of experimental argu-
ments have led to the concept that NO is not only involved in 
the control of vasomotor tone but also in vascular homeosta-
sis and neuronal and immunological functions. Endogenous 
NO is produced through the conversion of the amino acid, 
l-arginine to l-citrulline by the enzyme, NO-synthase (NOS) 
from which several isoforms have recently been isolated, 
puriﬁ  ed, and cloned. NOS-type I (isolated from brain) and 
type III (isolated from ECs) are termed “constitutive-NOS” 
and produce picomolar levels of NO from which only a 
small fraction elicits physiological responses. NO produced 
by NOS type III in the endothelium diffuses to the vascular 
smooth muscle (VSM) where it activates the enzyme guanyl-
ate cyclase. The concomitant increase in cyclic GMP then 
induces relaxation of the VSM.
The EC produces mediators that induce vasoconstriction, 
including endothelin (Haeﬂ  iger et al 1992; Cacoub 1993; 
Levin 1996), prostaglandins (Viberti 1989; Goldin et al 1996) 
and angiotensin II (ANG-II) (Studdy et al 1983; Hsueh and 
Anderson 1993; Rabelink and Bakris 1998; McFarlane 1999) 
and regulates vascular tone by maintaining a balance between 
vasodilation (NO production) and vasoconstriction (eg, A-II 
generation). ANG-II is produced in local tissues by the EC 
(Toop et al 1989; Mombouli 1997) and exerts regulatory 
effects upon several VSMC functional activities including 
contraction (ie, vasoconstriction), growth, proliferation, and 
differentiation. NOS also are regulated by local concentra-
tions of bradykinin (Busse et al 1993). This peptide acts with 
b2 receptors on the EC cell surface membrane, increasing the 
generation of NO via NOS activation. Interestingly, the local 
concentrations of bradykinin are regulated by the activity 
of angiotensin converting enzyme (ACE). ACE breaks Vascular Health and Risk Management 2007:3(6) 855
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down bradykinin into inactive peptides (Luscher et al 1993; 
Mombouli 1997).
Furthermore the EC has a prominent role in maintaining 
blood ﬂ  uidity and restoration of vessel wall integrity to 
avoid bleeding and plays a key role in the balance between 
the coagulation and ﬁ  brinolytic systems. In addition to its 
key role in growth and differentiation of the VSMC through 
the release of either promoters of growth and/or inhibitors 
of growth and differentiation and, as such, has an impact on 
vascular remodeling (Cowan and Langille 1996). However, 
strong evidence suggests that promotion of VSM growth is 
mediated by local production of platelet growth factor (PGF) 
and ANG-II (Williams 1998).
The EC is also involved in the production of speciﬁ  c 
molecules that have a regulatory role in inﬂ  ammation such 
as leukocyte adhesion molecule (LAM), intracellular adhe-
sion molecule (ICAM) and vascular cell adhesion molecule 
(VCAM). These molecules are denominated “adhesion 
molecules” and function to attract and “anchor” those cells 
involved in the inflammatory reaction. Very recently it 
has been demonstrated that the atherosclerotic process is 
associated with an increased blood level of inﬂ  ammation 
(acute phase proteins) markers (Tracy 1997; Biegelsen and 
Loscalzo 1999).
Endothelial dysfunction
and microalbuminuria
Microalbuminuria is usually deﬁ  ned as a urinary albumin 
excretion rate of 30–300 mg in a 24 h urine collection, or 
as a urinary albumin excretion rate of 20–200 mg/min in a 
timed overnight urine collection, although microalbuminuria 
was demonstrated to be a predictor for cardiovascular events 
at levels below these conventional cut-off values. It is an 
independent risk factor for the development of cardiovascular 
disease and a predictor of cardiovascular mortality in the 
diabetic population. It is associated with insulin resistance, 
atherogenic dyslipidaemia, and central obesity, the absence 
of nocturnal drop in both systolic and diastolic pressures and 
is a part of the metabolic cardiovascular syndrome associated 
with hypertension. Because microalbuminuria is related to 
endothelial dysfunction and increased oxidative stress, it is 
not surprising that diabetic atherosclerosis parallels diabetic 
glomerulosclerosis and is a very powerful risk factor for coro-
nary heart disease and stroke in diabetic persons. The impair-
ment of endothelium and NO-dependent vasodilation in the 
human forearm microcirculation in type 1 diabetic patients is 
more severe in the presence of microalbuminuria (Dogra et al 
2001). This defect was attributed to the presence of advanced 
glycosylation end products and/or increased generation of the 
superoxide anion in type 1 diabetic patients, both of which 
are known to effectively antagonize the biological activity 
of NO. Furthermore, basal NO-dependent vasodilatory tone 
has been found to be reduced in type 1 diabetic patients. 
Impaired NO biosynthesis has been demonstrated in the 
forearm vasculature of type 1 diabetic patients with micro-
albuminuria (Elliot 1993).
A cross-sectional association possibly exists between 
increased urinary albumin excretion and the presence of 
sub-clinical atherosclerosis (Jensen 2000), whether urinary 
albumin excretion increases before, during or after the 
development of morphological changes in the atherosclerotic 
process (in stage I, II or III), ie, whether microalbuminuria is 
a predictor of atherosclerosis or of atherosclerotic progres-
sion is not clear. Multiple markers of endothelial dysfunction 
have also been documented in normoalbuminuric subjects 
with type 2 diabetes, suggesting that the vasculopathy in type 
2 diabetes occurs early and may even be operative before the 
development of microalbuminuria (Lim et al 1999).
Endothelial dysfunction
and the metabolic syndrome
The metabolic syndrome is a highly prevalent multifaceted 
clinical entity produced through the interaction of genetic, 
hormonal and lifestyle factors. A distinctive constellation 
of abnormalities precedes and predicts the accelerated 
development of inﬂ  ammation and coagulation represent 
emerging risk contributors associated with obesity and 
insulin resistance, central components of the metabolic syn-
drome, which act in concert with traditional abnormalities to 
increase cardiovascular risk. The initiation and progression of 
atherosclerosis may have its origins in impaired endothelial 
function that can be detected at the earliest stages of develop-
ment of the syndrome. The basic elements of the metabolic 
syndrome and accelerated phase of atherogenesis are often 
silent partners that present many years before the onset of 
type 2 diabetes mellitus. The ability to detect and monitor 
sub clinical vascular disease, as a reﬂ  ection of the multiple 
factors that contribute to impair arterial wall integrity, holds 
potential to further reﬁ  ne cardiovascular risk stratiﬁ  cation 
(McVeigh and Cohn 2003).
Over time, insulin resistance is associated with more 
components of the metabolic syndrome (Table 1) including, 
low high density lipoprotein (HDL) cholesterol level, 
hypertension, increased vascular production of reac-
tive oxygen species, increased plasma PAI-1–mediated 
thrombotic tendency, hyperuricemia, high triglyceride levels Vascular Health and Risk Management 2007:3(6) 856
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and elevation of oxidation-prone small dense low-density 
lipoprotein (LDL) cholesterol levels. All are associated with 
endothelial dysfunction (McIntyre et al 1999; Toikka et al 
1999; Kita et al 2001; Matsuoka 2001). The incidence of 
the metabolic syndrome, as deﬁ  ned by the Adult Treatment 
Panel III report, increases with age. Carbohydrate intolerance 
occurs when the islet cells can no longer make enough insulin 
to overcome insulin resistance, and thus secreted insulin does 
not appropriately suppress hepatic glucose production. Free 
fatty acids may contribute to these changes, given that they 
can induce islet cell apoptosis and enhance liver gluconeo-
genesis (Arner 2003).
Free fatty acids and proinﬂ  ammatory adipokines likely 
contribute to endothelial dysfunction early in the course of 
insulin resistance. Free fatty acids induce endothelial dysfunc-
tion, whereas several adipokines promote both inﬂ  ammatory 
responses and insulin resistance (Steinberg et al 1997). The 
role of tumor necrosis factor TNF- in vascular inﬂ  ammation 
is well known, and a role for leptin is emerging (Fantuzzi 
and Faggioni 2000; Plutzky 2001). Adiponectin attenuates 
vascular inﬂ  ammatory changes, but its effects are reduced by 
its diminished expression in patients who are obese or have 
insulin resistance (Ouchi et al 2000, 2001; Yokota et al 2000). 
In the later stages of the metabolic syndrome, hyperglycemia 
contributes to the pathology by affecting signal transduction 
pathways, including those mediated through protein kinase C, 
in the endothelial cells (Tesfamariam et al 1999).
Insulin resistance in the natural 
history of type 2 diabetes
Insulin resistance, deﬁ  ned as the decreased ability of insulin 
to promote glucose uptake in skeletal muscle and adipose 
tissue and to suppress hepatic glucose output, may be present 
for many years before the development of any abnormality in 
plasma glucose levels (Kahn and Flier 2000; Haffner 2003).
The insulin resistance syndrome encompasses more than 
a subnormal response to insulin-mediated glucose disposal. 
Patients with this syndrome also frequently display elevated 
blood pressure, hyperlipidemia and dysfibinolysis even 
without any clinically demonstrable alteration in plasma 
glucose concentrations. Of note, endothelial dysfunction 
also has been demonstrated in patients with hypertension 
(Landin et al 1990; Luscher 1990; Bonner 1994; Briner and 
Luscher 1994; Kamide et al 1996; Lemne and de Faire 1996; 
Hedner and Sun 1997; Khder et al 1998), which is one of 
the features of the insulin resistance syndrome. It is tempting 
to speculate that loss of endothelial-dependent vasodilation 
and increased vasoconstrictors might be etiological factors 
of hypertension. Moreover loss of activity and/or quantity 
of endothelium-bound protein lipase activity may contribute 
to hyperlipidemia, which is typical of the insulin resistance 
syndrome. A synergistic interaction and vicious cycle may 
exist in which endothelial dysfunction contributes to insulin 
resistance and vice versa (Figure 1).
Insulin resistance has a well-known but not completely 
defined genetic influence, frequently transmitted along 
generations in any given family. Endothelial dysfunction 
has been demonstrated in insulin-resistant states in animals 
and humans and may represent an important early event 
in the development of atherosclerosis. Insulin resistance 
may be linked to endothelial dysfunction by a number of 
mechanisms, including disturbances of sub cellular signaling 
pathways common to both insulin action and NO produc-
tion. Other potential unifying links include the roles of 
oxidant stress, endothelin, the renin angiotensin system and 
the secretion of hormones and cytokines by adipose tissue. 
Individuals who advance toward the development of type 2 
diabetes experience progressive deterioration of glucose 
tolerance over time. In addition, obesity, which also has an 
important genetic component, invariably exacerbates any 
degree of insulin resistance (Kahn and Flier 2000). Thus, 
obesity and insulin resistance are usually present for many 
years before the appearance of other abnormalities such 
as hypertension, dyslipidemia, type 2 diabetes and cardio-
vascular disease. In certain individuals, obesity and insulin 
resistance may be present during childhood and adolescence 
(Goran et al 2003).
Increasing evidence suggest that hyperinsulinaemia 
is linked with the development of atherosclerosis in 
patients with diabetes. Whether hyperinsulinaemia directly 
affects neutrophil transendothelial migration and surface 
expression of related endothelial adhesion molecules were 
studied on healthy volunteers and from patients with non-
insulin-dependent diabetes mellitus across human umbilical 
vein. Endothelial cells cultured in insulin-rich medium using 
Table 1 Clinical identiﬁ  cation of the metabolic syndrome
Risk factor  Deﬁ  ning level
Abdominalobesity*(waistcircumference)† Men  102 cm
 Women  88 cm 
Triglycerides  150 mg/dL
High-density lipoprotein cholesterol  Men 40 mg/dL
 Women  50 mg/dL
Blood pressure  130/85 mm Hg
Fasting glucose  110 mg/dL
Diagnosis is made when three or more of the risk determinants are present 
(Hsueh et al 2004).Vascular Health and Risk Management 2007:3(6) 857
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cell-culture inserts high insulin (over 50 microU/ml for 
24 h) enhanced neutrophil transendothelial migration in a 
dose-dependent manner. This was associated with increased 
expression of platelet endothelial cell adhesion molecule-1 
(PECAM-1) but not of intercellular adhesion molecule-1 
(ICAM-1), P-selectin or E-selectin (Okouchi et al 2002).
Mechanisms of endothelial 
dysfunction in insulin resistance
Multiple, interrelated mechanisms contribute to endothelial 
cell dysfunction in insulin resistance. The exact mechanism 
by which dyslipidemia contributes to endothelial dysfunction 
is unknown. It is known that endothelial NOS inﬁ  ltrates into 
caveolae, which are cholesterol-rich invaginations present 
in endothelial cells and VSMC that decrease vasoconstric-
tive responses to angiotensin II, endothelin and constitutive 
endothelial NOS activity in animals (Rizzo 1998). Addition 
of oxidized LDL to cultured endothelial cells disrupts the 
caveolae complex and is thought to be associated with 
decreased endothelial NOS activity and endothelial dysfunc-
tion (Blair et al 1999; Drab et al 2001). HDL cholesterol can 
prevent the oxidized LDL–mediated decrease in cholesterol 
in caveolae, prevent the translocation of endothelial NOS 
and caveol in from caveolae, and prevent the decrease in 
responsiveness to acetylcholine (Uittenbogaard et al 2000). 
These effects occur because HDL cholesterol donates cho-
lesterol to the caveolae complex. These cellular events are 
consistent with the proatherogenic effects of LDL cholesterol 
and oxidized LDL cholesterol and the protective effects of 
HDL cholesterol.
The presence of hypertension and other atheroscle-
rotic risk factors is associated with increased vascular 
angiotensin II generation and activity (Dzau 2001). Because 
angiotensin II and insulin activate a common signaling 
pathway, increased sensitivity to angiotensin II may occur 
in the hyperinsulinemic, insulin-resistant state (Gaboury 
et al 1994). In addition, angiotensin II stimulates intracel-
lular adhesion molecule–1 and monocyte chemo-attractant 
protein–1 through the MAPK pathway in endothelial cells 
and VSMC (Chen et al 1998; Tummala et al 1999; Xi 
et al 1999). It is likely that many of the components of the 
metabolic syndrome directly alter endothelial vasoreactivity. 
However, these factors may decrease NO activity through 
oxidation pathways; the role of oxygen free radical is 
discussed bellow in Oxidative stress and endothelial cell 
dysfunction.
Role of hyperglycemia in diabetic 
endothelial dysfunction
Hyperglycemia is the major causal factor in the development 
of endothelial dysfunction in patients with diabetes mellitus 
(Figure 2). Clinical trials have identiﬁ  ed hyperglycemia 
as the key determinant in the development of chronic 
diabetic complications. The formation of advanced glyca-
tion end products (AGEs) is an important biochemical 
abnormality accompanying diabetes mellitus and, likely 
inﬂ  ammation in general. Although the mechanisms under-
lying this phenomenon are likely to be multi-factorial, 
recent in-vivo and in- vitro studies have indicated a crucial 
role of the diacylglycerol (DAG)-protein kinase C (PKC) 
pathway in mediating this phenomenon. PKC may have 
multiple adverse effects on vascular function, including 
the activation of superoxide-producing enzymes such as 
the nicotinamide adenine dinicleotide phosphate (NADPH) 
Insulin Resistance 
Hyperinsulinemia         Metabolic         Impaired glucose       Type 2 
Syndrome  Tolerance         Diabetes 
Endothelial                Inflammation                      Atherosclerosis 
Dysfunction               Thrombosis 
     Oxidation 
Figure 1 Progression of endothelial dysfunction in relation the progression of insulin resistance (Hsueh et al 2004).Vascular Health and Risk Management 2007:3(6) 858
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oxidase as well as increased expression of a dysfunctional, 
superoxide-producing, uncoupled endothelial nitric oxide 
synthase (NOS III). PKC-mediated superoxide production 
may inactivate NO derived from endothelial NOS III, and 
may inhibit the activity and/or expression of the NO down-
stream target, the soluble guanylyl cyclase. The effects 
of AGEs on vessel wall homeostasis may account for the 
rapidly progressive atherosclerosis associated with diabetes. 
Driven by hyperglycemia and oxidant stress, AGEs form to 
a greatly accelerated degree in diabetes. Within the vessel 
wall, collagen-linked AGEs may “trap” plasma proteins, 
quench NO activity and interact with speciﬁ  c receptors to 
modulate a large number of cellular properties. On plasma 
low density lipoproteins (LDL), AGEs initiate oxidative 
reactions that promote the formation of oxidized LDL. The 
interaction of AGEs with endothelial, as well as with other 
cells accumulating within the atherosclerotic plaque, such as 
mononuclear phagocytes and smooth muscle cells, provides 
a mechanism to augment vascular dysfunction. Speciﬁ  cally, 
the interaction of AGEs with vessel wall component increases 
vascular permeability, the expression of procoagulant activity 
and the generation of reactive oxygen species, resulting in 
increased endothelial expression of endothelial leukocyte 
adhesion molecules (Wen et al 2002; Hink et al 2003; Basta 
et al 2004; Farhangkhoee et al 2006), while acute hypergly-
cemia and hyperinsulinemia induced vasodilatation is not 
accompanied by changes in microvascular permeability or 
endothelial markers (Oomen et al 2002).
The effects of acute glycemia on plasma nitric oxide (NO; 
nitrite plus nitrate) levels, Cu-Zn Superoxide dismutase (Cu-Zn 
SOD) activity and thiobarbituric acid-reactive substances 
(TBARS) levels were studied in age-matched female subjects 
Hyperglycemia 
Polyol pathway  
   activity 
AGE 
formation  
Glucose
oxidation
PKC activation 
Antioxidant 
activity  
Arachidonic 
acid 
metabolism  
Increase oxidative stress 
Endothelial dysfunction  
Figure 2 Pathophysiology of hyperglycemia induced endothelial dysfunction (DeVriese et al 2000).Vascular Health and Risk Management 2007:3(6) 859
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before and two hours after glucose loading. Plasma NO levels 
were signiﬁ  cantly higher in subjects with diabetic glucose tol-
erance (DGT) than in subjects with normal glucose tolerance 
(p  0.001) and impaired glucose tolerance (IGT) (p  0.05) 
at baseline. TBARS levels were signiﬁ  cantly elevated in sub-
jects with DGT and IGT (p  0.001 and p  0.001). Cu-Zn 
SOD activities were signiﬁ  cantly increased in subjects with 
NGT, and were signiﬁ  cantly decreased in subjects with IGT 
and DGT (p  0.001 and p  0.001) after glucose loading; 
suggest that NO availability was decreased when the blood 
glucose levels were only moderately elevated above normal 
levels. This might be related with the enhanced oxidative stress 
(Konukoglu et al 2003).
Other studies examined the effect of acute hyperglycemia 
on endothelium-dependent vasodilation in patients with DM 
or impaired glucose metabolism in- vivo by plethysmogra-
phy. The vasodilatory response to acetylcholine at infusion 
rates of 7.5, 15, and 30 microg/min was studied in the fast-
ing state and at two levels of hyperglycemia, which were 
achieved by the infusion of glucose, insulin and somatostatin. 
The vasodilatory response to acetylcholine was measured by 
calculating the forearm blood ﬂ  ow ratio (FBFR), deﬁ  ned as 
the measured forearm blood ﬂ  ow at a speciﬁ  c acetylcholine 
infusion rate divided by the baseline forearm blood ﬂ  ow 
without acetylcholine infusion. The induction of hypergly-
cemia resulted in a signiﬁ  cant reduction in FBFR for all rates 
of acetylcholine infusion and suggests the importance of 
hyperglycemia in the development of endothelial dysfunction 
observed in patients with DM or impaired glucose metabo-
lism (Bhargava et al 2003; Kim et al 2003).
Oxidative stress and endothelial
cell dysfunction
Diabetic endothelium produces an increase in both O2 and 
H2O2 leading to enhanced intracellular production of OH. 
Thus, OH is implicated in diabetes-induced endothelial 
dysfunction (Tesfamariam et al 1992; Pieper et al 1997). 
Reactive oxygen species (ROS) are generated at sites of 
inﬂ  ammation and injury. ROS at low concentrations can 
function as signaling molecules participating as signaling 
intermediates in the regulation of fundamental cell activities 
such as cell growth and cell adaptation responses, whereas 
at higher concentrations, ROS can cause cellular injury and 
death. The vascular endothelium, which regulates the passage 
of macromolecules and circulating cells from blood to tissues, 
is a major target of oxidative stress, playing a critical role 
in the pathophysiology of several vascular diseases and 
disorders. Speciﬁ  cally, oxidative stress increases vascular 
endothelial permeability and promotes leukocyte adhesion, 
which is coupled with alterations in endothelial signal 
transduction and redox-regulated transcription factors (Hazel 
et al 2001). Decreased endothelium-dependent vasodilation 
in diabetic subjects is associated with the impaired action 
of NO secondary to its inactivation resulting from increased 
oxidative stress, rather than decreased NO production from 
vascular endothelium, and that abnormal NO metabolism is 
related to advanced diabetic microvascular complications 
(Maejima et al 2001).
Since ROS generation is increased in various disease 
states including DM and a direct reaction between NO and 
superoxide anion has been demonstrated, so a hypothesis 
suggest that inhibition of ROS will restore coronary micro-
vascular responses to ACh in a dog model of DM and topical 
application of superoxide dismutase (SOD) (250 U/ml) and 
catalase (250 U/ml) restored to normal ACh induced coronary 
microvascular responses in DM while having no affect in 
normal animals (Ammar et al 2000).
How is endothelial function 
assessed?
Endothelium-dependent vasodilatation can be assessed in 
the coronary and peripheral circulations. The most relevant 
methodological issues in the research on endothelial function 
and dysfunction have recently been published (Deanﬁ  eld 
et al 2005; Hadi et al 2005). We provide a summary of the 
available modalities of testing:
In coronary circulation, non-invasive tests for assessment 
of coronary endothelial function include Doppler echocar-
diography, positron emission tomography and phase-contrast 
magnetic resonance imaging were described. However, the 
gold-standard test for the evaluation of coronary endothelial 
function requires invasive coronary angiography; quantitative 
coronary angiography can be used to examine the changes in 
diameter in response to intracoronary infusions of endothelium-
dependent vasodilators such as acetylcholine. Endothelial 
function of the coronary microvasculature can be assessed with 
intracoronary doppler techniques to measure coronary blood 
ﬂ  ow in response to pharmacological or physiological stimuli 
(Anderson 1999; Al Suwaidi 2001; Farouque and Meredith 
2001). Diagnostic coronary angiography is ﬁ  rst performed with 
a standard femoral percutaneous approach. No nitroglycerin 
given before the diagnostic approach. Vasomotor responses to 
acetylcholine and adenosine then assessed (Al Suwaidi et al 
2001). After control coronary angiograms had been obtained, 
a 0.014- Inc Doppler guide wire is introduced through an 8F-
guiding catheter into the left anterior descending coronary Vascular Health and Risk Management 2007:3(6) 860
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artery (LAD). Once baseline ﬂ  ow velocity data are obtained 
at the position (when a stable doppler signal was obtained), a 
bolus of intracoronary adenosine (24–36 μg, from a solution 
of 6 mg adenosine in 1 L of saline) is administered. Then 
selective intra coronary infusion of increasing concentration 
of acetylcholine (10–6, 10–5, and 10–4 mol/L) is performed for 
a total 3 minutes through a 2.2 F Ultrafuse coronary infusion 
catheter. Symptoms, hemodynamic data, electrocardiographic 
and doppler velocities are recorded at the end of each infusion 
or bolus injection, followed by selective coronary angiogram. 
Coronary blood ﬂ  ow is calculated using the formula D² × APV , 
where D represents the coronary diameter and APV equals the 
average peak velocity from Doppler tracing.
In Peripheral Circulation, Brachial artery ultrasound is a 
widely used non-invasive measure of endothelial function. 
Upper-arm occlusion for 5 minutes results in reactive 
hyperemia after the cuff is released; this increase in shear 
stress results in endothelium-dependent flow-mediated 
vasodilatation. Importantly, endothelial dysfunction assessed 
by this technique correlates with measures of coronary 
endothelial dysfunction (Anderson et al 1995). Peripheral 
vascular endothelial function can be assessed by strain-
gauge venous impedance plethysmography. This technique 
examines the change in forearm blood ﬂ  ow in response 
to direct intra-arterial (brachial artery) administration of 
agonists. Non-invasive measures of arterial compliance and 
waveform morphology provide a marker of vascular health 
(Deanﬁ  eld et al 2005).
Molecular and cellular basis of 
endothelial dysfunction in diabetes
Hyperglycemia may lead to intracellular changes in the redox 
state resulting in depletion of the cellular NADPH pool. 
Accumulation of AGEs, whose formation is closely linked to 
oxidative stress, and resultant endothelial dysfunction may start 
early in the course of type 1 diabetes (Tsukahara et al 2003). 
Diminished capacity of nitric NOS to generate NO has been 
demonstrated experimentally when endothelial cells (ECs) 
were exposed either in-vitro or in-vivo to a diabetic environ-
ment (Arbogast et al 1982; Aanderud et al 1985; Koh et al 
1985; Lorenziet al 1986; Hattori et al 1991; Nordt et al 1993; 
Avogaro et al 1999; Cipolla 1999; Salvolini et al 1999).
Over expression of growth factors has also been impli-
cated as a link between diabetes and proliferation of both 
endothelial cells and vascular smooth muscle, possibly 
promoting neovascularization. Chronic hyperglycemia leads 
to non-enzymatic glycation of proteins and macromolecules 
(Jorge et al 2001). Insulin appears to regulate shedding or 
clearance of vascular adhesion protein-1 VAP-1, and an 
increase in sVAP-1. Therefore; absolute or relative insulin 
deﬁ  ciency may be directly involved in the pathogenesis of 
diabetic angiopathy (Salmi et al 2002).
The diabetic state is typiﬁ  ed by an increased tendency 
for oxidative stress and high levels of oxidized lipoproteins, 
especially the so-called small dense low density lipoprotein 
(LDL-C). High levels of fatty acids and hyperglycemia have 
both been shown to induce an increased level of oxidation 
of phospholipids as well as proteins. The diabetic state in 
humans is associated with a prothrombotic tendency as well 
as increased platelet aggregation; furthermore TNF has been 
implicated as a link between insulin resistance, diabetes and 
endothelial dysfunction. The hypothesis has been advanced 
in recent years that insulin and/or insulin precursors may be 
atherogenic (Jorge et al 2001). Recent study suggests that 
E-selectin may enhance CAD prediction beyond traditional 
risk factors or markers of oxidative stress in Type 1 diabe-
tes (Costacou et al 2005). Furthermore elevated circulating 
asymmetric dimethylarginine ADMA may contribute to the 
excess cardiovascular morbidity and mortality in early dia-
betic nephropathy (Tarnow et al 2004). In addition adverse 
metabolic stress factors in type 1 diabetes are associated 
with reduced angiogenicity, endothelial progenitor cells EPC 
numbers and function (by 44%) compared with age and sex 
matched control subjects (P  0.001). This reduction was 
inversely related to levels of HbA (1c) (R = –0.68, P = 0.01) 
using an in-vitro angiogenesis assay (Loomans et al 2004).
Role of adhesion molecules has been clariﬁ  ed in the last 
few years. Elevated level of slCAM-1 in young diabetic 
patients correlates with metabolic compensation and positive 
family history of cardiovascular diseases. sVCAM-1 level in 
diabetic children correlates signiﬁ  cantly positively with body 
mass index (BMI). Evaluation of adhesion molecules levels 
can be useful tool in the observation of the dynamic devel-
opment of early phases of atherosclerotic process in young 
patients with type 1 diabetes (Glowinska et al 2003).
We have reviewed all experimental and clinical studies 
from 1982–2006 that evaluated endothelial dysfunction in 
diabetic patients; most of which were prospective studies. 
Most of these studies in human indicate that endothelial 
dysfunction is closely associated to microangiopathy and 
atherosclerosis in diabetic patients.
Endothelial dysfunction in IDDM
The association between diabetes and endothelial dysfunction 
is particularly true in patients with type 1 diabetes who have 
either early (microalbuminuria) or late (macroalbuminuria) Vascular Health and Risk Management 2007:3(6) 861
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nephropathy. A variety of markers indicate endothelial 
dysfunction including: poor EC-dependent vasodilation, 
increased blood levels of von Willebrand factor (vWF), 
thrombomodulin, selectin, PAI-1, type IV collagen and t-PA 
were demonstrated in this patients population (Yaqoob et al 
1993; Dosquet et al 1994; Myrup et al 1994; Makimattila 
et al 1996; Huszka et al 1997; Cosentino and Luscher 
1998; Elhadd et al 1998; Malamitsi et al 1998; Huvers et al 
1999). Endothelial dysfunction was an early manifesta-
tion of vascular disease in type 2 diabetes but late in the 
course of type 1 diabetes (Clarkson et al 1996), furthermore 
studies have shown that the levels of cVCAM-1 were 
more markedly elevated in type 1 diabetes patients with 
diabetic retinopathy than in those patients with micro- or 
macroalbuminuria, whereas no difference in cICAM-1 
and cELAM-1 levels was apparent regarding the clinical 
status of diabetic microangiopathy (Fasching et al 1996). 
In diabetic subjects, endothelium-dependent vasodilation 
correlated inversely with serum insulin concentration but 
not with glucose concentration, glycosylated hemoglobin, 
or duration of diabetes (Johnston et al 1993). In a 10 year 
prospective study of 209 insulin-dependent diabetic patients 
with normal urinary albumin excretion has demonstrated 
coincidence of microalbuminuria and decreasing high density 
lipoprotein cholesterol, but no coincidence between onset of 
microalbuminuria and endothelial dysfunction assessed by 
von Willebrand factor (Myrup et al 1994; Hadi et al 2005). 
Little is known about the formation and accumulation of 
AGEs in young patients with type 1 diabetes. Patients with 
microalbuminuria ( or = 15 mg/g Cr) showed signiﬁ  cantly 
higher levels of pentosidine and pyrraline, and markers of 
oxidative stress, 8-hydroxy-2'-deoxyguanosine (8-OHdG) 
and acrolein-lysine than did normoalbuminuric patients and 
control. Of these four markers, urinary concentrations of 
pentosidine, 8-OHdG, and acrolein-lysine were signiﬁ  cantly 
higher in the patients with diabetes than in the healthy control 
subjects (Tsukahara et al 2003).
In another study a signiﬁ  cantly raised mean concentration 
of a free N-terminal ﬁ  bronectin 30-kDa domain was found 
in plasma of diabetic patients with proliferative retinopathy 
as compared with healthy persons, and a positive correlation 
was observed between free N-terminal ﬁ  bronectin and vWF 
and the degree of albuminuria. No relationship was found 
between ﬁ  bronectin and the degree of control of diabetes 
(Skrha et al 1990). In Participants from the Epidemiology 
of Diabetes Complications (EDC) cohort, a 10-year prospec-
tive study of childhood-onset Type 1 diabetes. Mean age at 
baseline was 28 years, and diabetes duration was 19 years. 
It has been found cellular adhesion molecules E-selectin may 
enhance CAD prediction beyond traditional risk factors or 
markers of oxidative stress in Type 1 diabetes (Costacou 
et al 2005).
Impaired FMD response is a common manifestation in 
children with type 1 diabetes and is associated with increased 
carotid artery intimae media thickness (IMT). Which may 
predispose them to the development of early atherosclero-
sis (Jarvisalo et al 2005). Although small dense LDL and 
oxidized LDL are features of type 2 diabetes and predict 
the development of coronary artery disease, their role in 
type 1 diabetes is less clear. One study has suggested, but 
do not prove, that LDL particle size and LDL vitamin E 
may be determinants of conduit and resistance vessel endo-
thelial vasodilator function in type 1 diabetes. Further work 
will be required to prove cause and effect (Skyrme-Jones 
et al 2001).
It is well known that pregnant women with diabetes 
mellitus have a higher incidence of adverse pregnancy 
outcomes. This issue has been assessed in a study which 
has found that the arteries obtained from the diabetic preg-
nant women did not demonstrate any difference in either 
endothelial or smooth muscle function when compared 
with non-diabetic pregnant women. The contribution of NO 
to endothelium-dependent relaxation was approximately 
20% in the pregnant women regardless of whether they 
were diabetic, and approximately 11% in the non-pregnant 
women (Ang et al 2002). In contrary in another small study 
the result of which need further conﬁ  rmation has found that 
although pregnancy enhances microvascular function, but in 
women with diabetes, such improvements are insufﬁ  cient to 
attain responses seen in healthy non pregnant women. And 
a persistent vascular defect in young women with type 1 
diabetes that may contribute to adverse pregnancy outcome 
(Ramsay et al 2003).
Endothelial dysfunction, as estimated by plasma vWF 
concentration, but not ﬁ  brinogen, precedes and may predict 
the development of microalbuminuria in IDDM (Stehouwer 
et al 1995; Verrotti et al 2003). The presence of endothelial 
dysfunction in normoalbuminuric diabetic patients suggests 
it could precede microalbuminuria as an early risk marker for 
cardiovascular disease (Dogra et al 2001). Recently a small 
study shows the vasomotor endothelial function in patients 
with diabetes mellitus (DM) type 1 at different stages of 
diabetic nephropathy (DN). ie, without renal affection, stage 
of microalbuminuria (MAU), proteinuria (PU), and chronic 
renal failure (CRF).in 26 patients with DM type 1 (11 males 
and 15 females, mean age 25.9 +/– 4.3 years, mean history of Vascular Health and Risk Management 2007:3(6) 862
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DM 12.9 +/– 3.4 years) and 7 healthy volunteers as control 
group. Endothelium-dependent vasodilation (EDVD) was 
assessed using test with reactive hyperemia provoked by 
4–5 min occlusion of the brachial artery by pneumocollar 
and subsequent assessment of arterial diameter changes 
after decompression using high-resolution ultrasound 
dopplerography conclude that at the earliest stage of diabetic 
nephropathy (stage MAU), EDVD is not affected as maximal 
vasodilation of the brachial artery and endothelial sensitivity 
to shift tension do not differ from the control values. This 
means that the stage of MAU is reversible in early treatment, 
but proteinuria and chronic renal failure are not reversible 
stages associated with depletion of endothelial cells and 
loss of sensitivity to changing hemodynamic conditions 
(Shestakova et al 2003). The role of endothelial dysfunction 
in the development and progression of cardio-renal syndrome 
in 93 patients with type 1 diabetes mellitus were studied by 
same investigator and analyzed endothelial ﬂ  ow-mediated 
dilation of the brachial artery, levels of endothelin-1, von 
Willerbrand factor, C-reactive protein, renal:albumin and 
protein excretion rates, glomerular ﬁ  ltration rate (GFR), 
and cardiovascular functions (ECG, echocardiography, 
blood pressure monitoring). GFR correlated positively with 
the coefﬁ  cient of sensitivity of endothelium to shear stress. 
Found a positive correlation between BP, permeability of 
glomerular ﬁ  lter and endothelial dysfunction markers and 
negative correlation with the coefﬁ  cient of sensitivity of 
endothelium to shear stress and GFR. Left ventricle mass 
correlated with markers of endothelial dysfunction and stage 
of renal disease (Shestakova et al 2005b).
More severe diabetic nephropathy was associated with 
higher prevalence of cardiac pathology. Frequency of isch-
emic heart disease was 13%, 33% and 53%, frequency of left 
ventricular concentric hypertrophy and remodeling 33%, 40% 
and 60% among patients with microalbuminuria, proteinuria 
and chronic renal failure, respectively. Abnormalities of 
24-hour blood pressure rhythm as well as signs of endothelial 
dysfunction were more pronounced in patients with more 
severe nephropathy. Correlation analysis revealed signiﬁ  cant 
relationships between markers of endothelial dysfunction, 
parameters of renal function, blood pressure level and mass 
of left ventricular myocardium. (Shestakova et al 2005a). 
Low plasma levels of active TGF-beta are associated with an 
impaired endothelial response and this may provide a useful 
tool for identifying Type 1 diabetic patients at a greater risk 
of coronary artery disease (Meeking et al 1999).
It is the general consensus that the occurrence of 
endothelial cell dysfunction in type 1 diabetes signiﬁ  es a 
very high risk of micro- and macroangiopathy and although 
the diabetic state predisposes to endothelial cell dysfunction 
in this disease, is not sufﬁ  cient to cause it. More likely, 
other agents (genes, environment) are likely to play a role 
in determining those patients that will develop aggressive 
angiopathy and hence endothelial cell dysfunction. Irrespec-
tive of whether endothelial cell dysfunction is a cause or a 
consequence of vascular injury in type 1 diabetes, therapeutic 
efforts aimed at restoring endothelial cell to normal will more 
likely have an affect on the natural history of vasculopathy 
in type 1 diabetes (Jorge et al 2001).
Plasma homocysteine levels
in type 1 diabetes and endothelial 
dysfunction
Although the ﬁ  ndings are inconsistent, moderate hyper-
homocysteinaemia (15–30 μmol/l) has been observed in 
some studies of patients with type 1 diabetes. Adolescent 
patients with no microvascular complications have lower 
(Chiarelli et al 2000; Cotellessa 2001; Wiltshire et al 2001) 
or similar (Pavia et al 2000) homocysteine levels compared 
with non-diabetic controls. Studies in adult patients have 
demonstrated similar (Hultberg et al 1991; Chico et al 1998; 
Vaccaro et al 2000), lower (Robillon et al 1994; Cronin et al 
1998) and higher (Hofmann 1998; Targher et al 2000) plasma 
homocysteine levels compared with non-diabetic controls. 
The homocysteine levels are independent of vitamin status 
and reﬂ  ect the heterogeneous nature of the patients studied, 
including patients with poor glycaemic control, variable 
duration of diabetes and a variety of microvascular and 
macrovascular complications. It would appear that certain 
subgroups are more likely to be associated with hyperhomo-
cysteinaemia; several factors have suggested: General factors; 
include genetic, nutrition, increasing age, male gender and 
renal failure. Factors speciﬁ  c to type 1 diabetes such as a 
lower age of onset of diabetes, poor glycaemic control, renal 
hyperﬁ  ltration and diabetic nephropathy. The interpretation 
of the result of these studies should be taken cautiously and 
further extensive work is needed to ﬁ  nalize this issue.
Endothelial dysfunction in NIDDM
The role of endothelial dysfunction in type 2 diabetes is 
more complicated than that for type 1. The effects of ageing, 
hyperlipidemia, hypertension and other factors add to the 
complexity of the problem. In contrast to patients with type 1 
diabetes, endothelial dysfunction can also occur in patients 
with type 2 diabetes even when the patients have normal 
urinary albumin excretion. In fact, markers of endothelial Vascular Health and Risk Management 2007:3(6) 863
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dysfunction are often elevated years before any evidence 
of microangiopathy becomes evident (Janka 1985; Hsueh 
and Anderson 1992; Bloomgarden 1998; De Mattia et al 
1998; Neri et al 1998; Watts and Playford 1998; Gazis 
et al 1999). The insulin resistance syndrome encompasses 
a subnormal response to insulin-mediated glucose disposal 
and frequently elevated blood pressure, hyperlipidemia and 
dysﬁ  binolysis, even without any clinically demonstrable 
alteration in plasma glucose concentrations (Steinberg et al 
1994). There is a growing body of evidence to suggest the 
coexistence of insulin resistance and endothelial dysfunction. 
Insulin-induced vasodilation, which is partially mediated 
by NO release, is impaired in obese individuals who do not 
have type 2 diabetes but whom display insulin resistance 
(Steinberg et al 1994; Ferri et al 1997; Cleland et al 2000). 
Moreover, the obese state, a model of human insulin resis-
tance, is associated with high levels of endothelin in plasma. 
Also blood concentrations of PAI-1 are high in patients 
with otherwise uncomplicated obesity (Calles et al 1996). 
Endothelial activation and acute-phase reaction correlate 
with insulin resistance and obesity in type 2 diabetic patients 
(Leinonen et al 2003).
Abnormalities in vascular reactivity and biochemical 
markers of endothelial cell activation are present early in 
individuals at risk of developing type 2 diabetes. The vasodi-
latory responses to acetylcholine were reduced in healthy nor-
moglycemic subjects who have ﬁ  rst degree diabetic relatives. 
The plasma levels of endothelin-1 were signiﬁ  cantly higher 
in subjects with impaired glucose tolerance and patients with 
type 2 diabetes without vascular complications compared 
with healthy normoglycemic subjects with no history of 
type 2 diabetes in a ﬁ  rst-degree relative (Caballero et al 
1999). In addition there is a signiﬁ  cant association between 
endothelial dysfunction and insulin resistance in young ﬁ  rst 
degree relatives of DM subjects independent of the classic 
cardiovascular risk factors (Balletshofer et al 2000).
In a case-cohort study, using the Monitoring of Trends 
and Determinants in Cardiovascular Disease (MONICA)/
Cooperative Research, men and women with elevated levels 
of sE-selectin had a signiﬁ  cantly increased risk of type 
2 diabetes after multivariable adjustment. Hazard ratios 
(95% CIs) comparing tertile extremes of sE-selectin were 
2.63 (1.79–3.88) and 1.71 (1.07–2.75) for men and women, 
respectively. Elevated levels of sICAM-1 were also associ-
ated with an increased risk of type 2 diabetes; however, the 
association was not independent of other diabetes risk factors 
including E-selectin, while vWF was not associated with 
risk of type 2 diabetes (Thorand et al 2006). A prospective, 
nested case-control study within the Nurses’ Health Study, 
has found elevated E-selectin and ICAM-1 levels can predict 
incident diabetes in logistic regression models conditioned on 
matching criteria and adjusted for body mass index (BMI), 
family history of diabetes, smoking, diet score, alcohol 
intake, activity index and postmenopausal hormone use. 
Adjustment for waist circumference instead of BMI or further 
adjustment for baseline levels of C-reactive protein, fasting 
insulin, and HbA1c or exclusion of cases diagnosed during 
the ﬁ  rst 4 years of follow-up did not alter these associations 
(Meigs et al 2004).
In diabetes, glycation, tissue oxidation and endothelial 
function are all abnormal and predisposing to microvas-
cular complications but interrelationships are complex 
with glycation appearing most direct (Wen et al 2002). 
The patients with microalbuminuria, unlike those without 
it, are characterized by longer course of diabetes, more 
pronounced lipid exchange disorder, more variable arterial 
pressure, higher pressure load index, elevated activity of 
lipid peroxidation (LP) processes and prominent disorder 
of NO-producing endothelial function. All improve with 
treatment (Ametov et al 2005). The Endothelium-dependent 
vasodilation was impaired in the microalbuminuric patients 
compared with the normoalbuminuria patients and the 
healthy controls. Plasma PAI-1 and vWF levels increased 
in the microalbuminuric patients compared with the levels 
in the normoalbuminuric patients and in the healthy controls 
(Yu et al 2004).
In type 2 diabetes mellitus as in type 1, increased calpain 
(calcium-dependent protease) activity in response to 
hyperglycemia may play a role in diabetic cardiovascular 
disease. Immunoprecipitation studies revealed that glucose 
induces loss of NO via a calpain-dependent decrease in the 
association of hsp90 with endothelial NOS. In addition, inhi-
bition of calpain activity decreased endothelial cell surface 
expression of the pro-inﬂ  ammatory adhesion molecules 
ICAM-1 and VCAM-1 during hyperglycemia (Stalker et al 
2003). Furthermore inhibition of PKC activity reduces 
leukocyte-endothelium interactions by suppressing surface 
expression of endothelial cell adhesion molecules in response 
to increased oxidative stress (Booth et al 2002).
In diabetes associated with diabetic microangiopathy, 
compared with non diabetics, asymmetric dimethylargi-
nine [ADMA]; an endogenous inhibitor of NOS, serum 
TNF-alpha and soluble TNF receptor I (sTNFR-I) has been 
assessed in a study which concludes that the serum sTNFR-I 
and VEGF levels were signiﬁ  cantly increased, but no differ-
ence in the serum TNF-alpha, sTNFR-II, and ADMA levels Vascular Health and Risk Management 2007:3(6) 864
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between uncomplicated diabetic patients and in non diabetics 
(Makino et al 2005).
Increased levels of vWF antigen, t-PA antigen and PAI-1 
activity were seen in impaired glucose tolerance (IGT) and 
diabetics compared with the normal glucose tolerance (NGT). 
Tissue factor pathway inhibitor TFPI activity and thrombo-
modulin levels were increased in all elderly subjects, with 
positive association between HbA (1c), TFPI activity and 
vWF antigen. Fasting blood glucose levels correlated with 
vWF antigen, t-PA antigen and PAI-1 activity, whereas 
urine albumin excretion correlated with TFPI activity, vWF 
antigen and PAI-1 activity. Serum insulin levels correlated 
strongly not only with vWF antigen and t-PA antigen but 
also with PAI-1 activity. This correlation did not change 
after further adjustment for serum glucose and HbA(1c), 
which may suggest that in the elderly subjects, impaired 
ﬁ  brinolysis is probably associated with insulin resistance 
(Leurs et al 2002). The above reﬂ  ect a prothrombotic state 
associated with an insulin resistance state, an increased vWF 
release, raised sP-Sel and TNFalpha levels and, may be, 
low NO bioavailability, which could lead to a higher risk of 
development of thrombotic events in hypertensive diabetic 
patients (Ouvina et al 2001).
NADPH oxidase gene expression is increased in circulating 
lymphomonocytes from patients with DM, and this increased 
gene expression is dependent upon metabolic control. 
Hyperglycemia can mediate its adverse effects through the 
activation of protein kinase C. Recent study has shown an 
increase in membrane-associated PKC beta 2 activity in 
monocytes from patients with DM. This activity was reduced 
by 40% in the euglycemic condition (Avogaro et al 2006). 
Further more patients with Type 2 diabetes with good residual 
C-peptide secretion are better protected from endothelial 
dysfunction that those with poor C-peptide secretion (Man-
zella et al 2003).
Endothelial dysfunction may have deleterious effect 
cardiovascular pathology in diabetic patients. Recent 
study found a signiﬁ  cant association between an abnormal 
SPECT result, left ventricular diastolic dysfunction and 
impaired post-ischaemic dilatation of the brachial artery. No 
association was found between the SPECT result, systolic 
function and left ventricular hypertrophy, however, an 
abnormal SPECT result was signiﬁ  cantly associated with 
left ventricular diastolic dysfunction and the deterioration 
of post-ischaemic dilatation of the brachial artery in asymp-
tomatic patients with type 2 diabetes (Charvat et al 2005). 
Myocardial blood ﬂ  ow (MBF) measured with positron emis-
sion tomography and 13N-ammonia to characterize coronary 
circulatory function in states of insulin resistance without 
carbohydrate intolerance (IR), impaired glucose tolerance 
(IGT), normotensive and hypertensive type 2 diabetes mel-
litus (DM) compared with insulin-sensitive (IS) individuals 
shows that endothelium-dependent coronary vasomotion 
was signiﬁ  cantly diminished in IR (–56%), as well as in 
IGT and normotensive and hypertensive diabetic patients 
(–85%, –91%, and –120%, respectively). Total vasodilator 
capacity was similar in normoglycemic individuals (IS, IR, 
and IGT), whereas it was signiﬁ  cantly decreased in normo-
tensive (–17%) and diabetic, hypertensive (–34%) patients 
(Prior et al 2005).
The phospho-Akt (Thr308) level in arteries from 
diabetic patients was reduced to about one-half of the 
level in non diabetic patients, suggesting impaired insulin 
signaling in human diabetic vascular tissue. Augmented 
vasoconstriction was observed in diabetic arteries, due in 
part to deﬁ  ciency of basal and stimulated NO production. 
This correlated with decreased endothelial NOS expres-
sion and activity in diabetic vessels (Okon et al 2005). 
The evaluation of enzymes implicated in the evolution of 
endothelial dysfunction associated with type 2 diabetes 
[lipoprotein-associated phospholipase A2, meloperoxidase 
(MPO) and paraoxonase (PON) activities] , may improve 
early diagnosis of CVD in asymptomatic patients with type 2 
diabetes and can help to evaluate accelerated atherosclerosis 
and microvascular disease (Moldoveanu et al 2006). A study 
recently, using high-resolution ultrasound, measured brachial 
artery responses to ﬂ  ow-mediated vasodilatation; (endothe-
lium-dependent vasodilatation) and nitroglycerine-induced 
vasodilatation; (endothelium-independent vasodilatation), 
compares non-traditional risk factors, such as endothelial 
function, plasma levels of CRP and adiponectin were mea-
sured by ELISA in Type 2 diabetic and non-diabetic patients 
following acute myocardial infarction. Twenty Type 2 dia-
betic patients were compared with 25 non-diabetic patients at 
baseline (1–3 days from the onset of chest pain) and at 60 days 
follow-up after an AMI. At 60 days follow-up, there were 
signiﬁ  cant differences in FMD (1.5 compared with 4.1%; 
P  0.02), CRP (4.23 compared with 1.46 mg/ml; P  0.01) 
and adiponectin (3.3 compared with 5.3 ng/ml; P  0.05) lev-
els between Type 2 diabetic and non-diabetic patients. These 
ﬁ  ndings may, in part explain, the poor outcome in coronary 
artery disease seen in Type 2 diabetes (Nystrom et al 2005). 
Type 2 diabetes is independently associated with impaired 
flow mediated dilatation (FMD). Hyperglycemia and 
hyperinsulinemia contribute minimally to this association. 
Impaired FMD may therefore, in part, explains the increased Vascular Health and Risk Management 2007:3(6) 865
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cardiovascular disease risk in DM2, whereas the normal FMD 
in impaired glucose metabolism (IGM) suggests that other 
forms of endothelial dysfunction are important in explain-
ing the increased cardiovascular disease risk in IGM (Henry 
et al 2004). On the other side, acute hyperinsulinaemia, both 
with and without concomitant hyperglycaemia, does not 
increase skin microvascular permeability, haemodynamics 
or parameters of endothelial dysfunction in Type 2 diabetic 
patients (Oomen et al 2004).
Patients with diabetes or hypertension have elevated 
ET-1 levels, but do not exhibit positive correlations between 
ET-1 levels and blood pressure, which was observed in healthy 
controls. Increased ET-1 levels do not induce hypertension 
in diabetes, but were lower in diabetic patients taking ACE 
inhibitors compared to those without ACE inhibitors. There 
is no signiﬁ  cant association between ET-1 levels and vascular 
complications. These ﬁ  ndings suggest that the plasma ET-1 
level is not a marker of endothelial dysfunction but changes 
in plasma ET-1 levels may precede vascular complications 
associated with hypertension and diabetes (Schneider et al 
2002). The same author studied plasma endothelin-1 (ET-1) 
levels in patients with diabetes mellitus or hypertension 
with healthy controls, and investigates whether ET-1 levels 
are correlated with glycemic control, metabolic parameters 
and vascular complications on 103 patients with type 1 
diabetes, 124 patients with type 2 diabetes, 35 hypertensive 
patients without diabetes mellitus and 99 controls. Patients 
with diabetes or hypertension have elevated ET-1 levels, but 
do not exhibit positive correlations between ET-1 levels and 
BP, which was observed in healthy controls. Increased ET-1 
levels do not induce hypertension in diabetes, but were lower 
in diabetic patients taking ACE inhibitors compared to those 
without ACE inhibitors. There is no signiﬁ  cant association 
between ET-1 levels and vascular complications (Schneider 
et al 2005). Furthermore the activity of endogenous ET-1 
on ET (A) receptors is enhanced in the resistance vessels of 
patients with diabetes, whereas their sensitivity to exogenous 
ET-1 is blunted (Cardillo et al 2002).
Well-controlled type 2 diabetic patients free of clinical 
macrovascular complications have elevated plasma markers 
of cardiovascular risk without having increased intima-
media thickness (IMT). The elevation of plasma markers 
of endothelial cell activation (sE-selectin and s-ICAM-1) or 
inﬂ  ammation (CRP) and oxidative stress (8-isoprostane) in 
diabetics vs. controls is distinct from and cannot be explained 
simply by differences in the burden of atherosclerosis as 
assessed by carotid intima-media thickness (Moussavi et al 
2004). Activation of poly (ADP-ribose) polymerase (PARP) 
is an important factor in the pathogenesis of endothelial 
dysfunction in diabetes. Destruction of islet cells with 
streptozotocin in mice induced hyperglycemia, intravascular 
oxidant production, DNA strand breakage, PARP activation 
and a selective loss of endothelium-dependent vasodilation. 
Treatment with a novel potent PARP inhibitor, starting after 
the time of islet destruction, maintained normal vascular 
responsiveness, despite the persistence of severe hypergly-
cemia (Garcia Soriano et al 2001).
Possible available therapy
Several therapeutic interventions have been tested in clinical 
trials aimed at improving endothelial function in patients with 
diabetes (Table 2). Insulin sensitizers may have a beneﬁ  cial 
effect in the short term, but the virtual absence of trials with 
cardiovascular end-points precludes any deﬁ  nitive conclusion. 
Two trials offer optimism that treatment with angiotensin 
converting enzyme inhibitors may have a positive impact 
on the progression of atherosclerosis (O’Driscoll et al 1997, 
Mullen et al 1998; Prasad et al 2000; Hornig et al 2001), 
although widely used, the effect of hypolipidemic agents on 
endothelial function in diabetes is not clear (Evans et al 2000). 
The role of antioxidant therapy is controversial.
Chronic cigarette smoking has a deleterious effect on 
plasma cICAM-1 levels in young type 1 diabetic patients, 
which further supports the clinical importance of discourag-
ing the initiation of smoking and promoting its cessation in 
people with type 1 diabetes (Zoppini et al 1999).
Children with type 1 diabetes have early endothelial 
dysfunction. Better folate status is associated with better 
endothelial function, as measured by higher FMD, higher 
FMD:GTN ratio, and lower thrombomodulin. Folate may 
therefore protect against endothelial dysfunction in children 
with diabetes (Wiltshire et al 2002).
Elevation in blood glucose and total glycosylated hemo-
globin in diabetic animals was normalized after islet trans-
plantation. Furthermore, islet transplantation completely 
restored the defective endothelium-dependent relaxation 
to acetylcholine in diabetic (Pieper et al 1995, 1996). Post-
prandial state is accompanied by endothelial dysfunction in 
Type 2 diabetic patients and that insulin aspart improved 
endothelial function (Ceriello et al 2004). Few studies 
have shown the beneﬁ  cial effect of insulin on endothelial 
dysfunction (Table 1). Long-term treatment with hydroxy-
methyl starch conjugated-deferoxamine had no effect on 
relaxation to nitroglycerin but completely prevented the 
impaired relaxation to acetylcholine in diabetic rats (Pieper 
and Siebeneich 1997).Vascular Health and Risk Management 2007:3(6) 866
Hadi and Suwaidi
Inhibition of rennin angiotensin 
pathway (Table 2A)
Angiotensin II has several pro-oxidative effects on the 
vasculature, decreasing NO bioavailability and resulting 
in vascular injury. ACE inhibitors are known to improve 
endothelial dysfunction, but the ability of angiotensin recep-
tor blockers to improve endothelial dysfunction is less clear 
(Mancini et al 1996; Taddei et al 2002). Both drug classes 
consistently prevent coronary artery (particularly in the 
case of ACE inhibitors), stroke, and diabetic microvascular 
complications of nephropathy and retinopathy (McFarlane 
et al 2003). Inhibition of the renin-angiotensin system is 
associated with reduced incidence of new-onset diabetes. In 
the Heart Outcomes Prevention Evaluation (HOPE) study 
(Yusuf et al 2001), the incidence of diabetes was 32% lower 
in the ramipril-treated group than in the placebo group. In the 
Losartan Intervention for Endpoint reduction in hypertension 
(LIFE) study (Dahlof et al 2002), losartan was associated with 
25% less new-onset diabetes compared with atenolol. The 
mechanisms responsible for the reduced incidence of diabetes 
observed during these trials are unknown, although possible 
mechanisms include increased plasma bradykinin levels, 
which improves insulin-mediated glucose uptake (Duka et al 
2001), improved endothelial function, increased vascular NO 
activity and reduced vascular inﬂ  ammation. More recent study 
in Chinese investigates the relationship between angiotensin 
converting enzyme (ACE) gene and endothelial dysfunction, 
concludes that, ACE DD genotype is related to endothelium-
dependent arterial dilation in the early stage of type 2 diabetes 
mellitus and in healthy individuals (Xiang et al 2004). Which 
may hope for gene therapy in the future?
Thiazolidinediones (Table 2A)
Thiazolidinediones enhances insulin-mediated glucose 
uptake into insulin target tissues, through activation of per-
oxisome proliferator-activated receptor (PPAR) (Mudaliar 
et al 2001). They have direct effects on adipose tissue by 
suppression TNF and, possibly, leptin expression; suppress 
lipolysis and thus decrease plasma free fatty acid concentra-
tions and increase plasma adiponectin levels (Hauner et al 
2001, 2002) and exert direct effects on insulin-mediated 
glucose transport in skeletal muscle and the heart (Bishop-
Bailey et al 2000; Loviscach et al 2000).
Thiazolidinedione administration reverses insulin resistance 
and many components of the metabolic syndrome. Treatment 
is generally associated with increased HDL cholesterol levels; 
decreased blood pressure, plasma triglyceride levels, small 
dense LDL cholesterol particles, PAI-1 levels and albumin 
excretion rates; in addition to decreased glucose levels and 
reduced hemoglobin A1C levels (Day 1999; Kruszynska et al 
2000; Lebovitz et al 2001; Freed et al 2002).
PPAR ligands also improve endothelial function (Dandona 
and Aljada 2004). Several studies have demonstrated 
improvements in brachial artery reactivity in patients with dia-
betes. (Avena et al 1998; Caballero et al 2003). Troglitazone 
(Watanabe et al 2000) and Rosiglitazone, improves coronary 
artery endothelial function in patients with insulin resistances 
who have no traditional risk factors for atherosclerosis as well 
as no impaired glucose tolerance or diabetes (Quin˜ones et al 
2002). With an increase in insulin sensitivity and a drop in 
fasting insulin and free fatty acid levels, thiazolidinediones 
in combination with hormone therapy (HT) in postmenopausal 
women is, however, have shown in study to attenuates endo-
thelial function (Honisett et al 2004).
The mechanisms by which thiazolidinediones improve 
endothelial-dependent blood ﬂ  ow are unknown, but likely 
involve several effects. First, as described above; it has an 
important anti-inﬂ  ammatory effects that involve decreasing 
circulating adipokines levels (eg, TNF, PAI-1, leptin), which 
are reﬂ  ected by reduced high-sensitivity C-reactive protein 
levels; increasing adiponectin levels; decreasing vascular 
expression of adhesion molecules (Wakino et al 2002). Second, 
insulin is a vasodilator stimulating expression of eNOS through 
the phosphatidylinositol 3-kinase (PI3K) pathway (Zeng et al 
2000).This effect of insulin is blunted in patients with insulin 
resistance (Kuboki et al 2000). PPAR- is expressed in endothe-
lial cells, and its ligands have been reported to enhance NO pro-
duction, possibly by stimulating the PI3K pathway and hence 
expression of eNOS (Kim et al 2002). Third, PPAR- ligands 
improve several components of the metabolic syndrome that 
could adversely affect endothelial function, including low HDL 
cholesterol levels, high triglyceride and free fatty acid levels, 
hypertension and carbohydrate intolerance. PPAR- ligands 
also decrease oxidative stress and thus are able to improve the 
vascular balance between NO and vasoconstrictors (Bagi et al 
2004). Rosiglitazone administration for 12 weeks was shown to 
improve insulin sensitivity and decrease asymmetric dimethyl-
arginine levels. An endogenous inhibitor of NOS, is associated 
with reduced NO–mediated vasodilation and enhanced adher-
ence of mononuclear cells to the endothelium (Chan et al 2000; 
Stuhlinger et al 2002). In recently performed a double-blind 
crossover trial of 12 patients with recently diagnosed type 
2 diabetes concludes that insulin resistance is a major con-
tributor toward endothelial dysfunction in type 2 diabetes; both 
endothelial dysfunction and insulin resistance are amenable 
to treatment by rosiglitazone (Pistrosch et al 2004). Recently Vascular Health and Risk Management 2007:3(6) 867
Endothelial dysfunction in diabetes mellitus
studies have shown that Rosiglitazone ameliorated glomerular 
hyperﬁ  ltration in early type 2 diabetes, improved NO bioavail-
ability and lessened renal end-organ damage in type 2 diabetes 
with microalbuminuria (Pistrosch et al 2005) and Pioglitazone 
improves endothelial dysfunction independently from the 
observed beneﬁ  ts on insulin sensitivity and beta-cell function 
in patients with newly diagnosed type 2 diabetes and CAD.and 
may exerts additional effects on endothelial function beyond 
metabolic control (Forst et al 2005; Sourij et al 2006). Further-
more the GATE study may provide the rationale and impetus 
Table 2A Role of various modalities of therapy on endothelial dysfunction 
Reference  Treatment  Patient  Result on endothelial function
  Role of ACEI and ARBs
Mancini et al 1996  ACEI (most studies)  NIDDM, CAD  +EDVD
O’Driscoll et al 1997,1999
Mullen et al 1998
Anderson et al 2000
Prasad et al 2000
Hornig et al 2001
Cheetham et al 2000  ARBs  NIDDM, CAD  Debated results
Hornig et al 2001
Hermann et al 2006  Quinapril 2 /12 Tx  24 pt. NIDDM,   ↑ insulin-stimulated endothelial function ,
     ↑ vascular adiponectin gene expression
Sato et al 2003  candesartan(4–12 mg-day)  30 pt. DM2,  clinically improves oxidant stress
    12 wks treatment 
Chaturvedi et al 2001  lisinopril  IDDM  Circulating plasma VEGF concentration is
      not strongly correlated with risk factor
      status or microvascular disease
Cheetham et al 2001  50 mg of losartan  NIDDM  ↑ NO-mediated dilation in the conduit vessels
  daily for 4 wks
Pieper et al 2000  temocapril  Diabetic rat  +EDVD
Arcaro et al 1999  Captopril 25 mg tid  IDDM  +EDVD in the femoral artery of
      normotensive microalbuminuric Pt.
O’Driscoll et al 1999  enalapril (10 mg twice  NIDDM  ↑ stimulated and basal
  daily / 4 wks    NO-dependent endothelial function.
McFarlane et al 1999  perindopril 4 for 12 wk  IDDM  improve arterial endothelial function
Gasic et al 1999  Fosinopril (10 mg/  11 microalbuminuric  ↓ cVCAM-1 levels and ↓ microalbuminuria
  day) for 12 wks  NIDDM pt.
Nielsen et al 1997  lisinopril 10–20 mg  43 hypertensive   reno- and vasculoprotective properties in
  dialy for12/12  NIDDM pts   hypertensive NIDDM nephropathy pts.
Bijlstra et al 1995  perindopril 4–8 mg  10 pt. NIDDM   +EDVD
  OD/ 6 /12
  Role of glitazones and other oral hypoglycemic agents
Sourij et al 2006  pioglitazone (30 mg/day  NIDDM  +EDVD
  for 12 wks
Caballero et al 2003  troglitazone treatment  NIDDM  +EDVD
  for 12 wks
Forst et al 2005  pioglitazone  179 pt. NIDDM  +EDVD
(Pistrosch et al 2005)  Rosiglitazone for  19 pt. NIDDM with.  ↓ glomerular hyperﬁ  ltration and NO
  12 wks  microalbuminuria  Bioavailability and ↓end-organ damage 
Hubacek et al 2004  Rotiglitazone  NIDDM  +EDVD
Pistrosch et al 2004
Tack et al 1998
Manzella et al 2005)  repaglinide (1 mg BID)  16 pt. NIDDM   improves brachial reactivity and
  for 4/12     ↓  oxidative stress indexes.
Bengel et al 2005  nateglinide 120 mg   47 pt. NIDDM  No effect myocardial blood ﬂ  ow
  t.i.d. 16 wks
De Mattia et al 2003  Gliclazide for 12 wk  15 pt NIDDM  improves both antioxidant status and
       NO-mediated  vasodilation
Katakam et al 2000  Metformin  NIDDM  +EDVD
Mather et al 2001Vascular Health and Risk Management 2007:3(6) 868
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for the aggressive treatment of insulin-resistant patients with 
glitazone therapy (Hubacek et al 2004).
Other antidiabetic
Repaglinide administration, through good control of 
postprandial glucose levels, improves brachial reactivity 
and declines oxidative stress indexes (Manzella et al 2005). 
While Nateglinide an oral antidiabetic insulinotropic agent 
neither improved nor impaired myocardial blood ﬂ  ow in 
Type 2 diabetic patients (Bengel et al 2005). Metformin; 
an antidiabetic agent that improves insulin sensitivity, 
treatment improved both insulin resistance and endothelial 
function, in animal and human (Katakam et al 2000; Mather 
et al 2001).
Statin and endothelial dysfunction 
(Table 2B)
Several clinical trials have demonstrated that statin treatment 
not only reduces serum cholesterol levels in hypercholes-
terolemic patients, but also substantially decreases the risk 
of cardiovascular disease (Shepherd et al 1995). In current 
clinical use, statins can reduce LDL cholesterol levels by 
an average of 20%–35%, with a corresponding 30%–35% 
reduction in major cardiovascular outcomes. Decreases in 
serum cholesterol levels could account for the observed 
risk reduction, since LDL cholesterol has a strong, well-
documented association with cardiovascular risk, and since 
plasma LDL apheresis has been shown to improve both 
endothelium-dependent vasodilation and cardiovascular 
risk in hypercholesterolemic patients (Thompson et al 1995; 
Tamai et al 1997). Several studies, however, have shown 
that improvements in endothelial function can occur before 
reductions in serum cholesterol levels. For example, ceriv-
astatin has been shown to improve endothelial function in 
elderly diabetic patients within 3 days, while, even more 
strikingly, healthy normocholesterolemic subjects have 
demonstrated markedly improved endothelial vasoreactivity 
after 3 hours (Tsunekawa et al 2001; Omori et al 2002). 
These acute effects are in agreement with other studies that 
have reported improvements in endothelial function after 
Table 2B Role of various modalities of therapy on endothelial dysfunction 
Reference  Treatment  Patient  Result on endothelial function
  Role of statin and other lipid lowering agent
Fegan et al 2005  cerivastatin  11 pt. NIDDM  improvement in microvascular
     endothelial  function 
Beishuizen et al 2005  0.4 mg cerivastatin  250 pt. NIDDM  no effect on FMD in type 2 diabetes
Joyce et al 2004  Pravastatin, 40 mg per  9 pt. IDDM  Improve (FMD)
 day  /1/12
Dalla Nora et al 2003  Atorvastatin for 1 year  25 pt. NIDDM  Improve (FMD)
van Venrooij et al 2002  30 wks’ Tx of atorvastatin   133 pt. NIDDM  Did not reverse endothelial dysfunction.
  10 mg & 80 mg
van Etten et al 2002  4 weeks of 80 mg   23 pt. NIDDM  no effect on NO availability in forearm
  atorvastatin daily    resistance arteries
Tan, Chow, Tam  atorvastatin (10 mg daily for 3/12,  80 pt. NIDDM  +EDVD,(signiﬁ  cant)
et al 2002  followed by 20 mg daily for 312)
van de Ree et al 2001  6-week Tx with simvastatin  17 pt. NIDDM  No effect
 40  mg/daily
Dumont et al 2001  Pravastatin (20 mg/kg/day)  Experimental rats  restores endothelial function
  for 2 wks
Tsunekawa et al 2001  cerivastatin (0.15 mg/d)   27 elderly NIDDM  improved impaired endothelial function 
  for 3 days    without affecting lipid proﬁ  les
Avogaro et al 2001  Gemﬁ  brozil 600 mg b.i.d,   10 pt. NIDDM  improves both insulin action and FMD
  for 12 wks
Evans et al 2000  Ciproﬁ  brate 3/12  NIDDM  improves fasting and postprandial 
     endothelial  function
 Role  of  insulin
Vehkavaara et al  insulin glargine and metformin  49 in vivo endothelial function  +EDVD and
2000, 2004    tests in 11 pt. NIDDM  endothelium-independent vasodilatation
Gaenzer et al 2002  insulin and metformin  21 poorly controlled  beneﬁ  cial effects on vascular function,
    NIDDM  resulting in enhanced EDD
Evans et al 2003  6 weeks of insulin lispro (0.2  20 pt. NIDDM  Improve endothelial dysfunction
  Iu kg-1) and vitamin C 1-g dailyVascular Health and Risk Management 2007:3(6) 869
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statin administration that do not correlate with reductions 
in serum LDL cholesterol levels (Kureishi et al 2000). 
Statins decrease high-sensitivity C-reactive protein levels 
by 30%–40%, independent of their cholesterol lowering 
capacities (Ansell et al 2003). Recent evidence also suggests 
that statins can improve insulin sensitivity. Cerivastatin has 
been shown to improve insulin sensitivity, as determined by 
hyperinsulinemic-euglycemic clamp, in patients with type 2 
diabetes after 3 months of treatment (Paniagua et al 2002). 
A similar study, in which patients with impaired fasting 
glucose levels were treated with atorvastatin for 16 weeks, 
noted a trend towards improved insulin sensitivity in the 
Table 2C Role of various modalities of therapy on endothelial dysfunction 
Reference  Treatment  Patient  Result on endothelial function
 Role  of  L-arginine
Sahach et al 2005  L-arginine  Porcine endothelialaortic  Prevent endothelial dysfunction
Kabat et al 2006    cells  
   (experimental) 
De Cobelli et al 2004  L-arginine  uremic IDDM pt.  induced vasodilatation of renal vls
Regensteiner et al 2003  1-week Tx of oral L-arginine (9 g daily)  10 premenopausaI  improved measures of endothelial
   or vitamins E (1800 mg) and C (1000 mg)  women with NIDDM
   function
 Role  of  antioxidants
Qian et al 2006  Injection of IL-2 (5000 and  diabetic rats  signiﬁ  cantly ameliorated the endothelia
  50,000 U/ kg/ d s.c.) for 5 wks    l dysfunction induced by hyperglycemia
Shemyakin et al 2006  A 60 minute intraarterial infusion of the   12 individuals with  enhances EDV in subjects with insulin
  ET(A) receptor antagonist BQ123    insulin resistance    resistance
  (10 nmol/min) combined with the ET(B)   with no any history 
  receptor antagonist BQ788 (5 nmol/min  of diabetes 
Zoukourian et al 1996  iloprost  Diabetic erythrocyte-  Alter endothelial dysfunction
   endothelium 
Clemens et al 1999  200 microg octreotide/day for 6/12  27 patients (IDDM).  Reduce endothelial dysfunction
Chowienczyk et al 2000  raxofelast (600 mg twice daily) for 1 wk.  10 pt. NIDDM  ↓ oxidative stress improves 
     endothelial  function
Bilsborough et al 2002  pentoxifylline 400 mg tid for 8 wks  13 pt. NIDDM  No effect on endothelial dysfunction
 Role  of  vitamins
MacKenzie et al 2006  folate (5 mg daily) & vitamin B6   124 children, IDDM  +EDVD in children with IDDM.
  (100 mg daily)   
McSorley et al 2005  vitamin E  14 pt. NIDDM  no effect
    
Pena et al 2004  oral folic acid (5 mg/d) and   36 subjects IDDM  improves endothelial function
Dhein et al 2003  8 wks vitamin E  Diabetic rat  prevent partially hyperglycemia-induce
      d endothelial dysfunction
Skyrme-Jones et al 2000  Vit E  NIDDM  +EDVD
Darko et al 2002  vitamin C 1.5 g daily in 3 doses for 3 wks  35 pt. NIDDM  No effect
Skyrme-Jones et al 2001  1000 IU vitamin E for 3/12  IDDM  No effect VCAM-1 and P-selectin
Heitzer et al 2000  tetrahydrobiopterin (500 microg/min)  23 pt, NIDDM  improves endothelial function
Skyrme-Jones et al 2001  vitamin E supplement (1,000 IU for 3/12)  IDDM  Improves (EVF)
Pinkney et al 1999  vitamin E 500 U/day 3/12  46 pt. IDDM  enhance FMD
 Others
Pieper et al 1997  50 mg/kg hydroxyethyl starch conjugated-  Diabetic rat  prevent diabetes-induced defects in
  deferoxamine for a total of 8 wks.    endothelium-dependent relaxation.
Fuchsjager-Mayrl et al 2002  aerobic exercise training   26 pt. IDDM  improve endothelial function in
      different vascular bed
Pieper et al 1996  Pancreatic cell transplantation  Diabetic rat  +EDVD
Maiorana et al 2001  combined aerobic & resistance exercise   16 pt. NIDDM  Improves endothelial vasodilator function
Shai et al 2004  Moderate alcohol intake  726 pt.NIDDM  ↓ inﬂ  ammation markers and endothelial 
    ( Health Professionals  dysfunction 
   Follow-up  Study) 
Abbreviations: NIDDM, non insulin dependent diabetes mellitus; IDDM, insulin dependant diabetes mellitus; FMD, ﬂ  ow mediated dilatation; EDVD, endothelial depen-
dant vasodilatation;   ACEI, angiotensin converting enzyme inhibitors;   ARBs, angiotensin receptor blockers, FMD, ﬂ  ow mediated dilatation; ET(A), endothelin(A), endothelial 
vasodilator function (EVF).Vascular Health and Risk Management 2007:3(6) 870
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treatment group, as determined by oral glucose tolerance test, 
but this trend failed to reach signiﬁ  cance (Costa et al 2003). 
Statin treatment did not, however, reduce the incidence of 
diabetes in at least one large prospective trial that addressed 
this question (Keech et al 2003).
Insulin therapy is it of help?
(Table 2B)
Low and high physiological hyperinsulinemia abolished 
endothelium-dependent vasodilation, whereas endothelium-
independent vasodilation was unaffected. Vitamin C fully 
restored insulin-impaired endothelial function without affect-
ing endothelium-independent vasodilation (Arcaro 2002). 
Other investigators concluded that insulin therapy partly 
restores insulin-stimulated endothelial function in patients 
with type 2 diabetes and ischemic heart disease (Rask et al 
2001). Another studies investigate long-term effects of 
insulin glargine on vascular function in patients with type 2 
diabetes, the result supports the idea that long-term insulin 
therapy has beneﬁ  cial rather than harmful effects on vascular 
function in type 2 diabetes (Paolisso and Giugliano 1996; 
Vehkavaara et al 2001).
Other modalities of therapy
(Table 2C)
Few sporadic studies has raised the Role of vitamins, the 
beneﬁ  t of L-arginine , antioxidant , and hydroxyethyl starch 
conjugated-deferoxamine aerobic exercise training and Pan-
creatic cell transplantation, the beneﬁ  t which need to clariﬁ  ed 
in more extensive studies .
Where we are from endothelial 
dysfunction in diabetes mellitus?
We think that we still far from the core pathological process 
in endothelial dysfunction, extensive research together with 
randomized trial are needed in this entity especially in molec-
ular biology and genetic engineering for more exploration of 
hidden aspect of iceberg. The future will witness increasing 
interest in ﬁ  nding reliable methods of testing endothelial 
function. As the measures of endothelial dysfunction become 
clinically applicable, this may translate into improved meth-
ods of risk assessment that help in predicting, preventing and 
treating cardiovascular disease. Inﬂ  ammatory markers, such 
as CRP, will probably ﬁ  nd their way into risk assessment; 
several therapeutic strategies aimed at improving endothelial 
function in diabetes mellitus states are under investigation. 
The future may holds great promise.
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